Silver Grove Financial Group’s Keros Therapeutics KROS Stock Holding History

Silver Grove Financial Group’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$86	Buy	+8	New	+$89	﹤0.01%	2352

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Silver Grove Financial Group's KROS Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Keros Therapeutics (KROS) in Q2 2026: 8 shares worth $86. The stake represents ﹤0.01% of the portfolio and ranks #2352 among its holdings.

132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Silver Grove Financial Group held 8 shares of Keros Therapeutics worth $86 as of Q2 2026.
Keros Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
Keros Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2352 holding.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.